adaura results: adjuvant osimertinib for egfrm non-small cell lung cancer
Published 3 years ago • 514 plays • Length 5:03Download video MP4
Download video MP3
Similar videos
-
2:13
overall-survival analysis of adaura: osimertinib in resected egfrm stage ib-iiia nsclc
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
6:20
asco 2023 highlights on adjuvant osimertinib in resected egfr mutated nsclc: the adaura trial
-
1:42
adaura: the benefit of adjuvant osimertinib
-
1:46
osimertinib after surgery significantly improves survival in resected egfr-mutated nsclc
-
6:23
adaura trial; early stage non–small cell lung cancer
-
6:30
osimertinib adjuvant therapy in patients with early stage egfr mutated nsclc after tumour resection
-
2:12
esmo 2020 highlights on adjuvant osimertinib for egfr mutated nsclc: the adaura study
-
3:31
osimertinib plus gefitinib for treatment of egfr-mutated non-small cell lung cancer
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
26:29
treatment of resected egfrm early lung cancer adjuvant osimertinib
-
15:35
asco 2020: latest developments in egfr-mutated non-small cell lung cancer
-
3:42
fda approves osimertinib as adjuvant therapy for non-small cell lung cancer with egfr mutations
-
4:24
reflections on the adaura study
-
10:20
role of adjuvant osimertinib in early stage nsclc
-
2:06
adaura trial: osimertinib for early stage egfr nsclc - 2022 program: targeted therapies forum
-
2:53
oleclumab plus osimertinib for advanced egfrm nsclc
-
4:25
adaura: osimertinib as adjuvant therapy in stage iii egfr nsclc
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc